CRESCENT BIOPHARMA, INC. (CBIO) Net margin 2016–2025
CRESCENT BIOPHARMA, INC. (CBIO) net profit margin by fiscal year — reported net income divided by reported revenue.
-1419.6%FY2025 · since FY2016: -171945.1% → -1419.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -1419.6% | — |
| FY2023 | -368994.2% | -306742.5 pp |
| FY2022 | -62251.7% | -56782.8 pp |
| FY2021 | -5469.0% | -4966.9 pp |
| FY2020 | -502.1% | — |
| FY2016 | -171945.1% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More CBIO financial trends
CBIO RevenueCBIO Net incomeCBIO Gross profitCBIO Gross marginCBIO Operating incomeCBIO Operating marginCBIO Operating cash flowCBIO Free cash flowCBIO Capital expendituresCBIO Return on equityCBIO Stock buybacksCBIO Dividends paidCBIO Total assetsCBIO Total liabilitiesCBIO Shareholders’ equityCBIO overview →